Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. | 2023 | Rheumatology International |
Cancer risk in patients treated with the jak inhibitor tofacitinib: systematic review and meta-analysis. | 2023 | Cancers |
Tofacitinib for acute severe ulcerative colitis: a systematic review. | 2023 | Journal of Chron’s and Colitis |
Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. | 2023 | Clinical Rheumatology |
Efficacy and safety of dual targeted therapy for partially or non-responsive inflammatory bowel disease: a systematic review of the literature. | 2023 | Digestive Diseases and Sciences |
The current role of tofacitinib in acute severe ulcerative colitis in adult patients: a systematic review. | 2023 | Digestive and Liver Disease |
Comparative of the effectiveness and safety of biological agents, small molecule drugs, and microbiome therapies in ulcerative colitis: systematic review and network meta-analysis. | 2023 | Medicine |
Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis. | 2023 | Frontiers in Pharmacology |
Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis. | 2023 | Frontiers in Pharmacology |
Safety of biologic and small molecule therapy for inflammatory bowel disease among solid organ transplant recipients: systematic review and meta-analysis. | 2023 | Inflammatory Bowel Diseases |
Relative remission and low disease activity rates of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate in patients with disease-modifying antirheumatic drug-naive rheumatoid arthritis. | 2023 | Pharmacology |
The comparative efficacy and safety of biologics and small molecules for treating patients with ulcerative colitis in Portugal: a systematic literature review and network meta-analysis. | 2023 | European Reviews for Medical and Pharmacological Sciences |
Risk of venous thromboembolism with Janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis. | 2023 | Frontiers in Pharmacology |
Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: a systematic review and meta-analysis. | 2022 | Frontiers in Immunology |
Association between Janus kinase inhibitors therapy and mental health outcome in rheumatoid arthritis: a systematic review and meta-analysis. | 2022 | Rheumatology and Therapy |
Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. | 2022 | Inflammatory Bowel Diseases |
Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis. | 2022 | International Journal of Rheumatic Diseases |
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis. | 2022 | International Journal of Clinical Pharmacy |
Comparative efficacy and safety of janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis. | 2021 | Therapeutic Advances in Musculoskeletal Disease |
Comparative efficacy and safety of peficitinib versus tofacitinib and baricitinib for treatment of rheumatoid arthritis: a systematic review and network meta-analysis. | 2021 | Rheumatology and Therapy |
Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. | 2021 | Therapeutic Advances in Gastroenterology |
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. | 2021 | The Cochrane Database of Systematic Reviews |
Current jakinibs for the treatment of rheumatoid arthritis: a systematic review. | 2021 | Inflammopharmacology |
Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. | 2020 | Mayo Clinic |
Risk of venous thromboembolism associated with tofacitinib and baricitinib: a systematic review and indirect meta‐analysis. | 2020 | Pharmacotherapy |
Efficacy of tofacitinib in the treatment of psoriatic arthritis: a systematic review. | 2020 | Advances in Therapy |
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. | 2020 | The Cochrane Database of Systematic Reviews |
Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis. | 2019 | Journal of International Medical Research |
Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. | 2019 | Therapeutic Advances in Musculoskeletal Disease |
Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. | 2019 | Annals of the Rheumatic Diseases |
Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals. | 2019 | Rheumatology International |
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. | 2019 | EULAR |